Financial Summary for Fiscal Year Ending March 2026 [IFRS] (Consolidated)

Performance Overview

In the fiscal year ending March 2026, M3, Inc. achieved revenue of ¥351,363 million (YoY +23.3%), operating income of ¥73,547 million (YoY +16.8%), profit before tax of ¥76,276 million (YoY +17.7%), net income of ¥54,046 million (YoY +21.9%), and net income attributable to owners of the parent of ¥49,100 million (YoY +21.3%), marking revenue and profit growth. By segment, Medical Platform, Patient Solutions, and Site Solutions performed strongly, with Patient Solutions revenue increasing by 159.5% due to effects from new consolidation. Cash flow from operating activities also increased to ¥70,262 million, strengthening the financial base.

Outlook and Shareholder Returns

For the fiscal year ending March 2027, continued revenue and profit growth is anticipated, with ongoing growth expected across all segments. The dividend is planned at ¥22.00 at year-end (YoY +¥1), representing a payout ratio of 30.3%. Additionally, a share buyback program has been decided with an acquisition limit of 20 million shares, a total acquisition amount cap of ¥20 billion, and an acquisition period from May 2, 2026 to April 30, 2027. This aims to improve capital efficiency and maximize shareholder value.